A
Anton C. Schoolwerth
Researcher at Dartmouth–Hitchcock Medical Center
Publications - 49
Citations - 11932
Anton C. Schoolwerth is an academic researcher from Dartmouth–Hitchcock Medical Center. The author has contributed to research in topics: Kidney disease & Population. The author has an hindex of 26, co-authored 49 publications receiving 11330 citations. Previous affiliations of Anton C. Schoolwerth include Virginia Commonwealth University & VCU Medical Center.
Papers
More filters
Journal ArticleDOI
Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.
Mark J. Sarnak,Andrew S. Levey,Anton C. Schoolwerth,Josef Coresh,Bruce F. Culleton,L. Lee Hamm,Peter A. McCullough,Bertram L. Kasiske,Ellie Kelepouris,Michael J. Klag,Patrick S. Parfrey,Marc A. Pfeffer,Leopoldo Raij,David J. Spinosa,Peter W.F. Wilson +14 more
TL;DR: There was a high prevalence of CVD in CKD and that mortality due to CVD was 10 to 30 times higher in dialysis patients than in the general population, and the task force recommended that patients with CKD be considered in the “highest risk group” for subsequent CVD events.
Journal Article
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
Shaul G. Massry,Jack W. Coburn,Glenn M. Chertow,Keith A. Hruska,Craig B. Langman,Hartmut H. Malluche,Kevin J. Martin,Linda McCann,James T. McCarthy,Sharon M. Moe,Isidro B. Salusky,Donald J. Sherrand,Miroslaw Smogorzewski,Kline Bolton,Charles Turkelson,Karyn A. Tappe,Stephen Tregear,James Reston,Wendy Bruening,Mark Monteforte,Janice Kaczmarek,Vivian Coates,George R. Bailie,Bryan N. Becker,Gavin J. Becker,Jerrilynn D. Burrowes,Fernando Carrera,David N. Churchill,Allan J. Collins,Peter W. Crooks,Dick DeZeeuw,Thomas A. Golper,Frank A. Gotch,Antonio M. Gotto,Roger Greenwood,Joel W. Greer,Richard H. Grimm,William E. Haley,Ronald J. Hogg,Alan R. Hull,Lawrence G. Hunsicker,Cynda Ann Johnson,Michael J. Klag,Saulo Klahr,Norbert Lameire,Francesco Locatelli,Sally McCulloch,Maureen Michael,Joseph V. Nally,John M. Newmann,Allen R. Nissenson,Keith C. Norris,Gregorio T. Obrador,William F. Owen,Thakor G. Patel,Glenda Payne,Claudio Ronco,Rosa A. Rivera-Mizzoni,Anton C. Schoolwerth,Robert A. Star,Michael W. Steffes,Theodore I. Steinman,John Pierre Wauters,Nanette K. Wenger,Josephine P. Briggs,Thomas H. Hostetter,Garabed Eknoyan,Aderra Levin,Nathan W. Levin,Sharon Andreoli,Sally Burrows-Hudson,Derrick Latos,Donna Mapes,Edith Oberley,Brian J.G. Pereira,Nadine Ferguson,Donna Fingerhut,Anthony Gucciardo,Margaret Klette,Doreen Mallard,Kerry Willis +80 more
Journal ArticleDOI
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
Mark J. Sarnak,Andrew S. Levey,Anton C. Schoolwerth,Josef Coresh,Bruce F. Culleton,L. Lee Hamm,Peter A. McCullough,Bertram L. Kasiske,Ellie Kelepouris,Michael J. Klag,Patrick S. Parfrey,Marc A. Pfeffer,Leopoldo Raij,David J. Spinosa,Peter W.F. Wilson +14 more
TL;DR: There was a high prevalence of CVD in CKD and that mortality due to CVD was 10 to 30 times higher in dialysis patients than in the general population, and the task force recommended that patients with CKD be considered in the “highest risk group” for subsequent CVD events.
Journal Article
K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease
Andrew S. Levey,Michael V. Rocco,Sharon Anderson,Sharon P. Andreoli,George R. Bailie,George L. Bakris,Mary Beth Callahan,Jane H. Greene,Cynda Ann Johnson,James P. Lash,Peter A. McCullough,Edgar R. Miller,Joseph V. Nally,John D. Pirsch,Ronald J. Portman,Mary Ann Sevick,Domenic A. Sica,Donald E. Wesson,Lawrence Y. Agodoa,Kline Bolton,Jeffrey A. Cutler,Tom Hostetter,Joseph Lau,Katrin Uhlig,Priscilla Chew,Annamaria T. Kausz,Bruce Kupelnick,Gowri Raman,Mark J. Sarnak,Chenchen Wang,Brad C. Astor,Garabed Eknoyan,Adeera Levin,Nathan W. Levin,George R. Bailie,Bryan N. Becker,Gavin J. Becker,Jerrilynn D. Burrowes,Fernando Carrera,David N. Churchill,Allan J. Collins,Peter W. Crooks,Dick DeZeeuw,Thomas A. Golper,Frank A. Gotch,Antonio M. Gotto,Roger Greenwood,Joel W. Greer,Richard H. Grimm,William E. Haley,Ronald J. Hogg,Alan R. Hull,Lawrence G. Hunsicker,Michael J. Klag,Saulo Klahr,Norbert Lameire,Francesco Locatelli,Sally McCulloch,Maureen Michael,John M. Newmann,Allen R. Nissenson,Keith C. Norris,Gregorio T. Obrador,William F. Owen,Thakor G. Patel,Glenda Payne,Claudio Ronco,Rosa A. Rivera-Mizzoni,Anton C. Schoolwerth,Robert A. Star,Michael W. Steffes,Theodore I. Steinman,John Pierre Wauters,Nanette K. Wenger,Josephine P. Briggs,Sally Burrows-Hudson,Derrick Latos,Donna Mapes,Edith Oberley,Brian J.G. Pereira,Kerry Willis,Anthony Gucciardo,Donna Fingerhut,Margaret Klette,Elicia Schachne +84 more
TL;DR: The purpose of the Executive Summary is to provide a "stand-alone" summary of the background, scope, methods, and key recommendations, as well as the complete text of the guideline statements.
Journal ArticleDOI
Renal Considerations in Angiotensin Converting Enzyme Inhibitor Therapy A Statement for Healthcare Professionals From the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association
TL;DR: Understanding the pathophysiological mechanisms and the common risk factors for ACE inhibitor–induced functional ARF is critical, because preventive strategies for ARF exist, and if effectively used, they may permit use of these compounds in a less restricted fashion.